Annovis’s Novel Approach To Parkinson’s Shows Early Promise
Also Targeting Alzheimer’s Disease
Executive Summary
Micro-cap Annovis Bio’s lead candidate has shown promise in nine patients with Parkinson’s, and could move into late-stage studies this year.
You may also be interested in...
Aducanumab Approval Decision Delayed: Could This Be Good News?
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.
Vertex Joins Regulus In Kidney Disease Therapy Hunt
The Boston, MA biotech is about to enter the clinic with its autosomal dominant polycystic kidney disease candidate but microRNA therapy pioneer Regulus is already setting the pace.